 |
|
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park
Clin Mol Hepatol. 2024;30(3):487-499. Published online 2024 May 7 DOI: https://doi.org/10.3350/cmh.2024.0145
|
|
Citations to this article as recorded by
 Dietary quality, perceived health, and psychological status as key risk factors for newly developed metabolic dysfunction–associated steatotic liver disease in a longitudinal study
Xuangao Wu, Ting Zhang, Sunmin Park
Nutrition.2025; 130: 112604. CrossRef A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis
Jeayeon Park, Goh Eun Chung, Yoosoo Chang, So Eun Kim, Won Sohn, Seungho Ryu, Yunmi Ko, Youngsu Park, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Gut and Liver.2025; 19(1): 126. CrossRef Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen
Cells.2025; 14(3): 221. CrossRef KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”
Jeayeon Park, Su Jong Yu
Clinical and Molecular Hepatology.2025; 31(2): 625. CrossRef Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Hai Xu, Yong Zhou, Huikun Wu
Clinical and Molecular Hepatology.2025; 31(2): e125. CrossRef Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Seogsong Jeong, Won Kim, Sang Min Park
Clinical and Molecular Hepatology.2025; 31(2): e210. CrossRef Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”
Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang
Clinical and Molecular Hepatology.2025; 31(2): e203. CrossRef Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Seogsong Jeong, Won Kim, Sang Min Park
Clinical and Molecular Hepatology.2025; 31(2): e208. CrossRef MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort st
Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song
Clinical and Molecular Hepatology.2025; 31(2): e128. CrossRef Significant hepatic fat loss after metabolic dysfunction-associated steatotic liver disease: Beware of misclassification as absence of disease
Seogsong Jeong
Journal of Hepatology.2025;[Epub] CrossRef Metabolic Dysfunction-Associated Steatotic Liver Disease in the Korean General Population: Epidemiology, Risk Factors, and Non-Invasive Screening
Yong Jun Choi, Jooheon Park, Han-Ik Cho, Myung Geun Shin, Eun-Hee Nah
Metabolites.2025; 15(5): 299. CrossRef Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease
Tom Ryu, Beom Sun Chung, Jaejun Lee, Ji Won Han, Hyun Yang, Keungmo Yang
Phytomedicine.2025; 143: 156889. CrossRef Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases
Jialong Wu, Gonghua Wu, Jiawei Li, Bo Yi, Qingyi Jia, Ke Ju, Qingyang Shi, Zixuan Wang, Xiong Xiao, Bing Guo, Huan Xu, Xing Zhao
European Journal of Endocrinology.2025; 192(5): 691. CrossRef Association between green space and hepatocellular carcinoma risk: a retrospective cohort study of seven South Korean metropolitan areas
Dong Hyun Kim, Seulggie Choi, Seogsong Jeong, Jooyoung Chang, Sung Min Kim, Sun Jae Park, Jun Hwan Kim, Joung Sik Son, Gyeongsil Lee, Soo Jung Choi, Yun Hwan Oh, Kyae Hyung Kim, Sang Min Park
International Journal of Environmental Health Research.2025; : 1. CrossRef Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review
Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro
Expert Review of Gastroenterology & Hepatology.2025; : 1. CrossRef Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study
Chae Won Lee, Eun Seok Kang, Seogsong Jeong, Hyun Wook Han, Samuel O. Antwi
PLOS One.2025; 20(6): e0323880. CrossRef All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study
Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho
JHEP Reports.2025; : 101477. CrossRef
|